Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05577416

A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (AB-218-IIT-201)

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Sponsor: AnHeart Therapeutics Inc.

Conditions Glioma

Interventions Biopsy Part A: Safusidenib Erbumine Part B: Safusidenib Erbumine Surgery (maximal resection)

Updated 4 times since 2022 Last updated: Jun 6, 2024 Started: Oct 11, 2022 Primary completion: Dec 1, 2024 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05577416, this EARLY_PHASE1 trial focuses on Glioma and remains actively recruiting participants. Sponsored by AnHeart Therapeutics Inc., it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1

Status: Active Not Recruiting → Recruiting
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Recruiting → Active Not Recruiting
Nov 2022 — Apr 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AnHeart Therapeutics Inc.
Melbourne Health
Walter and Eliza Hall Institute of Medical Research

Data source: Melbourne Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia